---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-26-000075"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2026-08-07T11:03:03+00:00"
generated_at: "2026-08-07T11:05:08.925811+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kiora Q2 2026 net loss $2.1M; cash $16.8M; ABACUS-2 higher-dose enrollment underway

## Summary
- Net loss $2.1M vs $2.2M YoY; R&D expense $2.1M net of $1.3M Théa reimbursement; G&A flat at $1.4M.
- Cash and short-term investments $16.8M at June 30, up from $13.9M at March 31; runway into late 2028.
- Private placement secured for up to $24M gross, $5M upfront, remainder contingent on milestone-based warrant exercise.
- ABACUS-2 Phase 2 (KIO-301) enrolling higher 100 µg dose cohort; last patient first visit Q1 2027, topline Q3 2027.
- KIO-104 KLARITY Phase 2 enrolling higher-dose cohort; initial clinical data expected late 2026.

## SEC filing metadata
- accession: 0001372514-26-000075
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2026-08-07T11:03:03+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/0001372514-26-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/kprx-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-26-000075
- JSON: https://secwatch.observer/filing/0001372514-26-000075.json
- Plain text: https://secwatch.observer/filing/0001372514-26-000075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.